Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia

Leukemia(2024)10.1038/s41375-024-02142-9Source: DataRank Database

State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia is a research paper published in Leukemia (2024). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

Linked data & code

geo gen gca

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 2.61)OA: hybridTopics (77)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Russell C. Rockne ORCID,Lisa Uechi ORCID,Dandan Zhao ORCID,Sergio Branciamore ORCID,Denis O’Meally ORCID

Live enrichment

PubMed:38307941 PMC:PMC10997512 OpenAlex:https://openalex.org/W4391482844

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Grant: U01CA250046

NCI NIH HHS

Grant: P30 CA033572

NCI NIH HHS

Grant: R01 CA258981

National Institutes of Health

Grant: 5R01CA250067-05

(PQ1) HIV-infected T-cell exosomes in lung cancer progression

National Institutes of Health

Grant: 5U01CA250046-04

Information flow and state transitions at the system and multi-dimensional scales in leukemia progression

National Institutes of Health

Grant: 5P30CA033572-27

Developmental Funds

FWCI

2.61

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

hybridLicense: cc-by

journalhttps://www.nature.com/articles/s41375-024-02142-9.pdf

publisherhttps://www.nature.com/articles/s41375-024-02142-9.pdf

publisherhttps://www.nature.com/articles/s41375-024-02142-9

journalhttps://doi.org/10.1038/s41375-024-02142-9

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38307941

Fields of Study

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and Treatment0302 clinical medicine03 medical and health sciences

MeSH Terms

AnimalsTetracyclinesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveFusion Proteins, bcr-ablDrug Resistance, NeoplasmProtein Kinase InhibitorsMiceTranscriptome

Keywords

TranscriptomeBiologyMyeloid leukemiaCancer researchLeukemiaDiseaseImmunologyGeneGeneticsGene expressionMedicineInternal medicineTetracyclines (mesh)bcr-ablDrug ResistanceFusion Proteins, bcr-ablMice1103 Clinical Sciences (for)2.1 Biological and endogenous factorsAnimals (mesh)Chronic32 Biomedical and Clinical Sciences (for-2020)CancerCancer (rcdc)Mice (mesh)3201 Cardiovascular medicine and haematology (for-2020)Protein Kinase Inhibitors (mesh)Hematology1112 Oncology and Carcinogenesis (for)TetracyclinesBCR-ABL Positive (mesh)bcr-abl (mesh)Neoplasm (mesh)BiotechnologyImmunology (science-metrix)570Oncology and CarcinogenesisClinical Sciences610Biotechnology (rcdc)Cardiovascular medicine and haematologyArticleRare Diseases (rcdc)Rare DiseasesLeukemia, Myelogenous, Chronic, BCR-ABL Positive3211 Oncology and carcinogenesis (for-2020)AnimalsProtein Kinase InhibitorsHematology (rcdc)Biomedical and Clinical SciencesGenetics (rcdc)4.1 Discovery and preclinical testing of markers and technologies (hrcs-rac)Fusion Proteins2.1 Biological and endogenous factors (hrcs-rac)Cancer (hrcs-hc)3202 Clinical sciences (for-2020)Transcriptome (mesh)4.1 Discovery and preclinical testing of markers and technologiesOrphan DrugDrug Resistance, NeoplasmOrphan Drug (rcdc)NeoplasmBCR-ABL PositiveMyelogenous

Sustainable Development Goals

SDG 0: Good health and well-being